Sophia Genetics
Helps clinicians and physicians predict genetic diseases better.
- B2B
- saas
- subscription
- health
- enterprise software
- biotechnology
- pharmaceutical
- artificial intelligence
- big data
- deep tech
- machine learning
- deep learning
- nanotech
- biotechnology
- dt and ls
- spinout
- core ai
- analytics
- ai applications
- data analytics
- genetics and genomics
- verified unicorns and $1b exits
- dna
- drug development
- genome engineering
- tech for hospitals and clinics
- tech for medical professionals
- techbio
- knowledge management
- insurtech related
- digital pharma
- medical imaging
- clinical decision support
- precision medicine
- from $1b exit to zebra
- techscale200
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | $50.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 42 % | 18 % | 31 % | 4 % | 14 % | 24 % | 26 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (168 %) | (173 %) | (99 %) | (84 %) | (67 %) | (46 %) | (18 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (182 %) | (184 %) | (127 %) | (96 %) | (86 %) | (56 %) | (29 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 66 % | 74 % | 59 % | 53 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Sophia Genetics is a healthcare analytics startup that operates in the field of data-driven medicine. The company's primary offering is the SOPHiA DDM™ Platform, a cloud-based system powered by artificial intelligence (AI) and machine learning (ML). This platform allows healthcare providers to standardize, compute, and analyze digital health data, generating insights that can improve diagnosis, therapy selection, analysis, and drug development.
Sophia Genetics serves a wide range of customers, including hospitals, research institutions, and pharmaceutical companies. These customers perform testing on their own samples, retain ownership of their data, and use the SOPHiA DDM™ Platform to analyze this data. They can also share their insights with each other, contributing to a collective intelligence that can improve patient outcomes worldwide.
The company operates in a global market, with a particular focus on genomic profiling. This involves analyzing a patient's genetic information to understand their susceptibility to certain diseases, such as cancer or inherited disorders. The SOPHiA DDM™ Platform can analyze complex multimodal data sets, which means it can handle different types of data at the same time.
Sophia Genetics makes money by charging its customers for access to the SOPHiA DDM™ Platform. This business model allows the company to generate revenue while also contributing to the democratization of data-driven medicine.
Keywords: Healthcare Analytics, Data-Driven Medicine, Genomic Profiling, Artificial Intelligence, Machine Learning, Cloud-Based Platform, Digital Health Data, Collective Intelligence, Global Market, Business Model.
Tech stack
Investments by Sophia Genetics
Edit
